Anthem Biosciences anticipates a revenue of INR 2,124 crore in FY26, marking an 18% increase. The Q4 revenue reached INR 611 crore, growing by 26% year-over-year. The company plans to invest INR 1,200 crore in capital expenditure for the years FY27 and FY28.

Anthem Biosciences reported a significant Q4 FY26 net profit increase of 104.4% compared to the previous quarter and 129.7% year-on-year, but its stock dropped 0.9% to ₹780.25 due to concerns about potentially high valuations.

Anthem Biosciences aims to achieve a 20% long-term growth by expanding its production capacity significantly, signaling potential growth opportunities in the biotech sector.

Anthem Biosciences sees a significant jump in Q4 net profit, doubling from last year's ₹826M to ₹1.9B. The company also reported an increase in revenue for the same period, reaching ₹6.1B compared to ₹4.8B recorded in the previous year.

Anthem Biosciences has revealed their key financial metrics such as revenue, EBITDA, and profit after tax, which mainly pertain to their CRDMO and Specialty Ingredients sectors. These figures have been authenticated by Chartered Accountants.

Citigroup has given a positive outlook on Anthem Biosciences, predicting a price of ₹870 based on anticipated growth in their CRDMO (Contract Development and Manufacturing Organization) segment. The financial firm estimates a robust revenue growth rate of 26% for FY23-26, along with a steady EBITDA growth rate of 22% from FY26-28.

Citi Group now recommends buying shares in Anthem Biosciences, predicting the stock could reach ₹870. Investors might want to consider this bullish forecast for Anthem Bio's future.